- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-7961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Severe asthma and the omalizumab option ; volume:6 ; number:1 ; day:20 ; month:5 ; year:2008 ; pages:1-13 ; date:12.2008
Clinical and molecular allergy ; 6, Heft 1 (20.5.2008), 1-13, 12.2008
- Creator
-
Miller, Christopher WT
Krishnaswamy, Narayanaswamy
Johnston, Chambless
Krishnaswamy, Guha
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-7961-6-4
- URN
-
urn:nbn:de:101:1-2019111719552634554338
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miller, Christopher WT
- Krishnaswamy, Narayanaswamy
- Johnston, Chambless
- Krishnaswamy, Guha
- SpringerLink (Online service)
Other Objects (12)
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab as successful treatment option in severe peanut allergy
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Omalizumab in three children with severe vernal keratoconjunctivitis
Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab as successful treatment option in severe peanut allergy
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Omalizumab in three children with severe vernal keratoconjunctivitis
Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Omalizumab as successful treatment option in severe peanut allergy
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Omalizumab in three children with severe vernal keratoconjunctivitis